Research Study for adults with Fatty Liver Disease

IRB/UVA Tracking #
Principal Investigator
Stephen H Caldwell
Jennifer Greene
Contact Email
Contact Phone
Official Trial Title
A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic
Steatohepatitis (NASH) with Open-Label Part to Evaluate the Safety, PK and Tr
Study Description

The Division of Gastroenterology and Hepatology seeks: adults ages 18-75 with fatty liver disease (NASH) for a research study. The purpose of the study is to evaluate the twice daily dosing of an investigational medication, Aramchol, on NASH and NASH-related complications compared to placebo and to examine its safety.

You may be eligible for this study if you have NASH (or your doctor is evaluating you for NASH) and you do NOT have cirrhosis.

Study involves taking an experimental medicine/placebo for up to 5 years, blood draws, up to 3 liver biopsies over the 5 years of treatment and electrocardiograms at each visit. There are 7 visits to UVA during the first year of the study and 4 visits per year for each of the 4 years following the first.

Study-related exams, tests and experimental medication are all provided free of charge.


No Compensation